Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment

Autor: Julio Abucham, Rogerio Silicani Ribeiro
Přispěvatelé: Universidade Federal de São Paulo (UNIFESP)
Rok vydání: 2009
Předmět:
Zdroj: Repositório Institucional da UNIFESP
Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
ISSN: 1479-683X
0804-4643
Popis: ContextPersistence of hypogonadism is common in male patients with prolactinomas under dopamine agonist (DA) treatment. Conventional therapy with testosterone causes undesirable fluctuations in serum testosterone levels and inhibition of spermatogenesis.ObjectiveTo evaluate the use of clomiphene as a treatment for persistent hypogonadism in males with prolactinomas.DesignOpen label, single-arm, prospective trial.PatientsFourteen adult hypogonadal males (testosterone InterventionClomiphene (50 mg/day orally) for 12 weeks.MeasuresTestosterone, estradiol, LH, FSH, and prolactin were measured before and 10 days, 4, 8, and 12 weeks after clomiphene. Erectile function, sperm analysis, body composition, and metabolic profiles were evaluated before and after clomiphene.ResultsTen patients (71%), five hyperprolactinemic and two normoprolactinemic, responded to clomiphene (testosterone >300 ng/dl). Testosterone levels increased from 201±22 to 457±37 ng/dl, 436±52, and 440±47 ng/dl at 4, 8, and 12 weeks respectively (0.001
Databáze: OpenAIRE